Regen BioPharma, Inc. Announces Program to Accelerate Checkpoint Inhibitor Program Using Modified mRNA and SiRNA Technologies

SAN DIEGO, March 10, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has announced a program to accelerate the clinical development of its NR2F6 therapies. The Company intends to combine the modified mRNA technology with Regen’s existing intellectual property on siRNAs (small interfering RNAs) targeting the nuclear receptor NR2F6 which has been identified as a potentially very important inhibitor of immune cells (a immune checkpoint) and a cancer stem cell differentiator.

mRNA is a single-stranded molecule that carries the genetic code from DNA in the nucleus of a cell to the ribosomes (the protein-making machinery of the cell).

Regen has filed an Investigational New Drug Application (IND #16928) for its drug called tCellVax with the US FDA. tCellVax is intended to use siRNA to silence NR2F6 activity in human immune cells, thereby activating these immune cells in such a way that they can attack cancer cells. The Company believes that the addition of new intellectual property using the modified mRNA will profoundly simplify the drug development process and thus accelerate development.

Dyo Biotechnology ( ) was hired to assist Regen in the development of the aforementioned technology.

“I believe that our drug tCellVax as it stands today is a potentially major new development in the field of cancer immunotherapy. We believe that by adding our new mRNA intellectual property to tCellVax, we we can simplify its administration to patients and thereby create a much more marketable drug,” says David Koos, CEO and President of Regen. “An RNA-based checkpoint inhibitor will be a first-class drug.”

Regen is in the process of drafting a new patent application relating to this intellectual property.

About Regen BioPharma Inc.:

Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the field of immunology and immunotherapy. The company is focused on rapidly advancing new technologies through preclinical and Phase I/II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for the treatment of cancer and autoimmune diseases. Additional information about Regen BioPharma is available at

Warning: This announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those stated, contemplated or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Regen BioPharma Inc.
David R. Koosdoctorate
+1-619-722-5505 Telephone
+1-619-330-2328 Fax
[email protected]

Follow us on Twitter for future updates:

SOURCERegen BioPharma, Inc.

Comments are closed.